UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 619

Sortiert nach

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Leukemia, 2015-05, Vol.29 (5), p.1123-1132

2015

Link zum Volltext

Verfügbarkeit prüfen

Atem / Breath: Gestalterische, ökologische und soziale Dimensionen / Morphological, Ecological and Social Dimensions

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Leukemia, 2017-11, Vol.31 (11), p.2398-2406

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Leukemia, 2017-11, Vol.31 (11), p.2523-2525

2017

Link zum Volltext

Verfügbarkeit prüfen

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2017-02, Vol.52 (2), p.317-320

2017

Link zum Volltext

Verfügbarkeit prüfen

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Leukemia, 2012-11, Vol.26 (11), p.2353-2359

2012

Link zum Volltext

Verfügbarkeit prüfen

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

European journal of cancer (1990), 2017-11, Vol.86, p.233-239

2017

Link zum Volltext

Verfügbarkeit prüfen

NFATc1 as a therapeutic target in FLT3-ITD-positive AML

Leukemia, 2015-07, Vol.29 (7), p.1470-1477

2015

Link zum Volltext

Verfügbarkeit prüfen

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Leukemia, 2017-04, Vol.31 (4), p.829-836

2017

Link zum Volltext

Verfügbarkeit prüfen

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Leukemia, 2015-06, Vol.29 (6), p.1331-1335

2015

Link zum Volltext

Verfügbarkeit prüfen

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells

Leukemia, 2007-06, Vol.21 (6), p.1267-1275

2007

Link zum Volltext

Verfügbarkeit prüfen

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Bone marrow transplantation (Basingstoke), 2013-03, Vol.48 (3), p.403-407

2013

Link zum Volltext

Verfügbarkeit prüfen

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Leukemia, 2018-04, Vol.32 (4), p.1054-1054

2018

Link zum Volltext

Verfügbarkeit prüfen

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

The lancet oncology, 2018-06, Vol.19 (6), p.747-757

2018

Link zum Volltext

Verfügbarkeit prüfen

Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2

Blood, 2004-05, Vol.103 (9), p.3480-3489

2004

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia

Leukemia, 2006-03, Vol.20 (3), p.437-443

2006

Link zum Volltext

Verfügbarkeit prüfen

Differential diagnosis of pericardial effusion after stem cell transplantation in acute myeloic leukemia

Herz, 2011-06, Vol.36 (4), p.352-354

2011

Link zum Volltext

Verfügbarkeit prüfen

Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option

Deutsche medizinische Wochenschrift (1946), 2010-09, Vol.135 (38), p.1852

2010

Link zum Volltext

Verfügbarkeit prüfen

Immune regulatory plasmacytoid dendritic cells selectively accumulate in perithyroidal lymph nodes of patients with Graves disease: implications for the understanding of autoimmunity

Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, 2013-01, Vol.117 (1), p.46-51

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer

Langenbeck's archives of surgery, 2006-11, Vol.391 (6), p.589-596

2006

Link zum Volltext

Verfügbarkeit prüfen

Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines

Endocrine, 2007-04, Vol.31 (2), p.105-113

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 619

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(551)
Mit Volltextzugriff
(554)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(331)
Life Sciences & Biomedicine
(315)
Humans
(252)
Male
(134)
Female
(131)
Middle Aged
(109)
Adult
(91)
Aged
(83)
Hematology
(72)
Oncology
(71)
Radiology, Nuclear Medicine & Medical Imaging
(67)
Biological And Medical Sciences
(64)
Medical Sciences
(59)
Social Sciences
(44)
Cardiovascular System & Cardiology
(40)
Cardiac & Cardiovascular Systems
(38)
Psychology
(36)
Medicine
(35)
Medicine & Public Health
(32)
Treatment Outcome
(32)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

Atem / Breath: Gestalterische, ökologische und soziale Dimensionen / Morphological, Ecological and Social Dimensions

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Long-term survival of sorafenib-treated FLT3-ITD–positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

NFATc1 as a therapeutic target in FLT3-ITD-positive AML

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia

Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR/ABL and down-regulates bcl-2

Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Differential diagnosis of pericardial effusion after stem cell transplantation in acute myeloic leukemia

Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option

Immune regulatory plasmacytoid dendritic cells selectively accumulate in perithyroidal lymph nodes of patients with Graves disease: implications for the understanding of autoimmunity

European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer

Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines

Suchergebnisse filtern